T2DM pharmacological protocols mainly target the endogenous response to glucose stimulation by increasing insulin sensitivity, insulin secretion, and glucose uptake (Marín-Peñalver et al., 2016). The gene discussed is INS; the disease is type 2 diabetes mellitus.